167 related articles for article (PubMed ID: 36327880)
1. Potential dual inhibition of SE and CYP51 by eugenol conferring inhibition of Candida albicans: Computationally curated study with experimental validation.
Prajapati J; Goswami D; Dabhi M; Acharya D; Rawal RM
Comput Biol Med; 2022 Dec; 151(Pt A):106237. PubMed ID: 36327880
[TBL] [Abstract][Full Text] [Related]
2. New miconazole-based azoles derived from eugenol show activity against Candida spp. and Cryptococcus gattii by inhibiting the fungal ergosterol biosynthesis.
Campos Péret VA; Reis RCFM; Braga SFP; Benedetti MD; Caldas IS; Carvalho DT; Santana LFA; Johann S; Souza TB
Eur J Med Chem; 2023 Aug; 256():115436. PubMed ID: 37146343
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ergosterol synthesis in Candida albicans by novel eugenol tosylate congeners targeting sterol 14α-demethylase (CYP51) enzyme.
Lone SA; Khan S; Ahmad A
Arch Microbiol; 2020 May; 202(4):711-726. PubMed ID: 31786635
[TBL] [Abstract][Full Text] [Related]
4. A Comprehensive in vitro and in silico Assessment on Inhibition of CYP51B and Ergosterol Biosynthesis by Eugenol in Rhizopus oryzae.
Prajapati J; Rao P; Poojara L; Acharya D; Patel SK; Goswami D; Rawal RM
Curr Microbiol; 2022 Dec; 80(1):47. PubMed ID: 36538133
[TBL] [Abstract][Full Text] [Related]
5. Structural analyses of
Hargrove TY; Friggeri L; Wawrzak Z; Qi A; Hoekstra WJ; Schotzinger RJ; York JD; Guengerich FP; Lepesheva GI
J Biol Chem; 2017 Apr; 292(16):6728-6743. PubMed ID: 28258218
[TBL] [Abstract][Full Text] [Related]
6. Terbinafine: mode of action and properties of the squalene epoxidase inhibition.
Ryder NS
Br J Dermatol; 1992 Feb; 126 Suppl 39():2-7. PubMed ID: 1543672
[TBL] [Abstract][Full Text] [Related]
7. Evolution of ergosterol biosynthesis inhibitors as fungicidal against Candida.
Ahmad A; Khan A; Manzoor N; Khan LA
Microb Pathog; 2010 Jan; 48(1):35-41. PubMed ID: 19835945
[TBL] [Abstract][Full Text] [Related]
8. Comparison and analysis of the structures and binding modes of antifungal SE and CYP51 inhibitors.
Sun B; Huang W; Liu M; Lei K
J Mol Graph Model; 2017 Oct; 77():1-8. PubMed ID: 28802152
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
Sun B; Dong Y; An Y; Liu M; Han J; Zhao L; Liu X
Eur J Med Chem; 2020 Nov; 205():112645. PubMed ID: 32791399
[TBL] [Abstract][Full Text] [Related]
10. Effects of squalene epoxidase inhibitors on Candida albicans.
Georgopapadakou NH; Bertasso A
Antimicrob Agents Chemother; 1992 Aug; 36(8):1779-81. PubMed ID: 1416865
[TBL] [Abstract][Full Text] [Related]
11. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei.
Onyewu C; Blankenship JR; Del Poeta M; Heitman J
Antimicrob Agents Chemother; 2003 Mar; 47(3):956-64. PubMed ID: 12604527
[TBL] [Abstract][Full Text] [Related]
12. Potent arylamide derivatives as dual-target antifungal agents: Design, synthesis, biological evaluation, and molecular docking studies.
Dong Y; Liu X; An Y; Liu M; Han J; Sun B
Bioorg Chem; 2020 Jun; 99():103749. PubMed ID: 32220664
[TBL] [Abstract][Full Text] [Related]
13. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme.
Warrilow AG; Hull CM; Parker JE; Garvey EP; Hoekstra WJ; Moore WR; Schotzinger RJ; Kelly DE; Kelly SL
Antimicrob Agents Chemother; 2014 Dec; 58(12):7121-7. PubMed ID: 25224009
[TBL] [Abstract][Full Text] [Related]
14. Construction and activity evaluation of novel dual-target (SE/CYP51) anti-fungal agents containing amide naphthyl structure.
Liu W; Sun Z; An Y; Liu Y; Fan H; Han J; Sun B
Eur J Med Chem; 2022 Jan; 228():113972. PubMed ID: 34772530
[TBL] [Abstract][Full Text] [Related]
15. Anti-Candida, docking studies, and in vitro metabolism-mediated cytotoxicity evaluation of Eugenol derivatives.
Dutra JAP; Maximino SC; Gonçalves RCR; Morais PAB; de Lima Silva WC; Rodrigues RP; Neto ÁC; Júnior VL; de Souza Borges W; Kitagawa RR
Chem Biol Drug Des; 2023 Feb; 101(2):350-363. PubMed ID: 36053023
[TBL] [Abstract][Full Text] [Related]
16. Ergosterol biosynthesis inhibition by the thiocarbamate antifungal agents tolnaftate and tolciclate.
Ryder NS; Frank I; Dupont MC
Antimicrob Agents Chemother; 1986 May; 29(5):858-60. PubMed ID: 3524433
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding.
Xiao L; Madison V; Chau AS; Loebenberg D; Palermo RE; McNicholas PM
Antimicrob Agents Chemother; 2004 Feb; 48(2):568-74. PubMed ID: 14742211
[TBL] [Abstract][Full Text] [Related]
18. Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors.
Vanden Bossche H; Marichal P
Am J Obstet Gynecol; 1991 Oct; 165(4 Pt 2):1193-9. PubMed ID: 1951574
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of resistance to azole antifungals.
Lupetti A; Danesi R; Campa M; Del Tacca M; Kelly S
Trends Mol Med; 2002 Feb; 8(2):76-81. PubMed ID: 11815273
[TBL] [Abstract][Full Text] [Related]
20. The Aspergillus fumigatus Damage Resistance Protein Family Coordinately Regulates Ergosterol Biosynthesis and Azole Susceptibility.
Song J; Zhai P; Zhang Y; Zhang C; Sang H; Han G; Keller NP; Lu L
mBio; 2016 Feb; 7(1):e01919-15. PubMed ID: 26908577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
